Interní Med. 2016; 18(3): 120-123 | DOI: 10.36290/int.2016.029

News in the treatment of bronchial asthma in adults

MUDr. Lucie Heribanová
Pneumologická klinika 1. LF UK a Thomayerovy nemocnice

This article informs about new possibilities in the treatment of severe refractory asthma, including the possibility of using tiotropium,

macrolides and biological treatment for asthma.

Keywords: asthma bronchiale, biological therapy, azithromycin, tiotropium

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heribanová L. News in the treatment of bronchial asthma in adults. Interní Med. 2016;18(3):120-123. doi: 10.36290/int.2016.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sedlák V, Chlumský J, Teřl M, et al. Doporučený postup diagnostiky a léčby obtížně léčitelného bronchiálního astmatu, 2011. (http://www.pneumologie.cz/guidelines).
    2. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804-813. Go to original source...
    3. Teřl M, Čáp P, Dvořáková R, et al. Doporučený postup diagnostiky a léčby bronchiálního astmatu. ČPFS, ČSAKI, ČSPD 2014, Dostupné nawww.pneumologie.cz.
    4. Teřl M. Současné možnosti léčby těžkého astmatu v ČR. Remedia 2012; 22-24: 248-252.
    5. Teřl M, Pohunek P, et al. Strategie diagnostiky, prevence a léčby astmatu. Praha: ČIPA, Jalna, 2012.
    6. Kašák V. Asthma bronchiale. Praha: Jessenius/Maxdorf, 2005.
    7. Databáze léků - Relvar Ellipta, Flutiform, Fullhale, Airflusan Forspiro, Duoresp Spiromax. Dostupné na www.sukl.cz.
    8. Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 2012; 129: 48-59. Go to original source... Go to PubMed...
    9. SPC Spiriva Respimat 2,5mikrogramů. Dostupné na www.sukl.cz.
    10. Kerstens H, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207. Go to original source...
    11. Crosbie PAJ, Woodhead MA. Long term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33: 171-181. Go to original source... Go to PubMed...
    12. Good JTJ, Rollins DR, Martin RJ. Macrolides in the treatment of asthma. Curr Opin Pulm Med 2012; 18: 76-84. Go to original source...
    13. Brusselle G, Joosa G. Is there a role for macrolides in severe asthma? Curr Opin Pulm Med 2014; 11: 13-19. Go to original source...
    14. Brusselle G, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double blind placebo controlled trial. Thorax 2013; 68: 322-329. Go to original source...
    15. Colice GL. Emerging therapeutic options for asthma. Am J Manag Care 2011; 17(Suppl 3): 82-89.
    16. Braunová J. Biologická léčba astmatu - historie a budoucnost nových léčebných možností. Remedia. 2010; 20(1): 69-72.
    17. Beck LA, Marcotte GV, Macglashan D, et al. Omalizumab induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527-530. Go to original source... Go to PubMed...
    18. Morjaria JB, Polosa R. Off label use of omalizumab in nonasthma conditions: new opportunities. Expert Rev Resp Med 2009; 3: 299-308. Go to original source... Go to PubMed...
    19. Xolair - souhrn údajů o přípravku. Dostupné na http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.
    20. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015, dostupné na: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/09/news_detail_002395.jsp&mid=WC0b01ac058004d5c1.
    21. Nucala - Summary of product charakteristics. dostupné na: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdf.
    22. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double blind, placebo controlled trial. Lancet 2012; 380: 651-659. Go to original source...
    23. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine, 371(13): 1189-1197. Go to original source...
    24. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine, 371(13): 1198-1207. Go to original source...
    25. Caruso M, Crisafulli E, Lizzio R, Polosa R. Biologic therapy for atopic asthma and beyond. Curr Opin Allergy Clin Immunol. 2013; 13(6): 677-685. Go to original source...
    26. Gruenberg D, Busse WW. Biologic therapies for asthma. Curr Opin Pulm Med, 2010; 16: 19-24. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.